Cargando…

Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1

The autoimmune reaction against the beta cells of the pancreatic islets in type 1 diabetes mellitus (T1DM) patients is active in prediabetes and during the development of the clinical manifestation of T1DM, but it decreases within a few years of the clinical manifestation of this disease. A key role...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben-Skowronek, Iwona, Sieniawska, Joanna, Pach, Emilia, Wrobel, Wiktoria, Skowronek, Anna, Tomczyk, Zaklina, Rosolowska, Iga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745590/
https://www.ncbi.nlm.nih.gov/pubmed/35008819
http://dx.doi.org/10.3390/ijms23010390
_version_ 1784630382106247168
author Ben-Skowronek, Iwona
Sieniawska, Joanna
Pach, Emilia
Wrobel, Wiktoria
Skowronek, Anna
Tomczyk, Zaklina
Rosolowska, Iga
author_facet Ben-Skowronek, Iwona
Sieniawska, Joanna
Pach, Emilia
Wrobel, Wiktoria
Skowronek, Anna
Tomczyk, Zaklina
Rosolowska, Iga
author_sort Ben-Skowronek, Iwona
collection PubMed
description The autoimmune reaction against the beta cells of the pancreatic islets in type 1 diabetes mellitus (T1DM) patients is active in prediabetes and during the development of the clinical manifestation of T1DM, but it decreases within a few years of the clinical manifestation of this disease. A key role in the pathogenesis of T1DM is played by regulatory T cell (Treg) deficiency or dysfunction. Immune interventions, such as potential therapeutic applications or the induction of the Treg-cell population in T1DM, will be important in the development of new types of treatment. The aim of this study was to evaluate innovative immune interventions as treatments for T1DM. After an evaluation of full-length papers from the PubMed database from 2010 to 2021, 20 trials were included for the final analysis. The analysis led to the following conclusions: Treg cells play an important role in the limitation of the development of T1DM, the activation or application of Tregs may be more effective in the early stages of T1DM development, and the therapeutic use of Treg cells in T1DM is promising but requires long-term observation in a large group of patients.
format Online
Article
Text
id pubmed-8745590
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87455902022-01-11 Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1 Ben-Skowronek, Iwona Sieniawska, Joanna Pach, Emilia Wrobel, Wiktoria Skowronek, Anna Tomczyk, Zaklina Rosolowska, Iga Int J Mol Sci Review The autoimmune reaction against the beta cells of the pancreatic islets in type 1 diabetes mellitus (T1DM) patients is active in prediabetes and during the development of the clinical manifestation of T1DM, but it decreases within a few years of the clinical manifestation of this disease. A key role in the pathogenesis of T1DM is played by regulatory T cell (Treg) deficiency or dysfunction. Immune interventions, such as potential therapeutic applications or the induction of the Treg-cell population in T1DM, will be important in the development of new types of treatment. The aim of this study was to evaluate innovative immune interventions as treatments for T1DM. After an evaluation of full-length papers from the PubMed database from 2010 to 2021, 20 trials were included for the final analysis. The analysis led to the following conclusions: Treg cells play an important role in the limitation of the development of T1DM, the activation or application of Tregs may be more effective in the early stages of T1DM development, and the therapeutic use of Treg cells in T1DM is promising but requires long-term observation in a large group of patients. MDPI 2021-12-30 /pmc/articles/PMC8745590/ /pubmed/35008819 http://dx.doi.org/10.3390/ijms23010390 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ben-Skowronek, Iwona
Sieniawska, Joanna
Pach, Emilia
Wrobel, Wiktoria
Skowronek, Anna
Tomczyk, Zaklina
Rosolowska, Iga
Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1
title Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1
title_full Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1
title_fullStr Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1
title_full_unstemmed Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1
title_short Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1
title_sort potential therapeutic application of regulatory t cells in diabetes mellitus type 1
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745590/
https://www.ncbi.nlm.nih.gov/pubmed/35008819
http://dx.doi.org/10.3390/ijms23010390
work_keys_str_mv AT benskowronekiwona potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1
AT sieniawskajoanna potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1
AT pachemilia potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1
AT wrobelwiktoria potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1
AT skowronekanna potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1
AT tomczykzaklina potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1
AT rosolowskaiga potentialtherapeuticapplicationofregulatorytcellsindiabetesmellitustype1